Trial Profile
Phase3 Study to Evaluate the Efficacy and Safety of AlbuminInterferon in Combination With Ribavirin Compared With Peginterferon in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC Genotype 2/3
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Albinterferon alfa 2B (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ACHIEVE-2/3
- Sponsors Human Genome Sciences
- 05 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 03 Jul 2012 Planned number of patients changed from 920 to 928 as reported by European Clinical Trials Database.
- 29 Aug 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry).